INTRODUCTION

Ecthyma contagiosum, also called the orf disease, is a zoonotic skin infection caused by the orf virus (OrfV) that belongs to the family of *parapoxvirus*. It is transmitted to humans by direct contact with infected animals (such as sheep and goats) or by contaminated fomites and meat. It is a self-limiting condition in immunocompetent patients and typically resolves after several weeks without any specific treatment. However, in immunocompromised patients such as cases with a history of organ transplant, orf usually manifests as giant, persistent and atypical lesions. Herein, we present a case of recurrent, giant digital orf in a female patient with a past medical history of hairy cell leukemia.

Received: 31 March 2022 | Revised: 9 June 2022 | Accepted: 25 July 2022
DOI: 10.1002/ccr3.6209
leukemia in addition to a literature review on cases of orf in immunocompromised patients.

2 | CASE PRESENTATION

A 70-year-old woman with an enlarging tumor on the dorsum of her right second finger presented to our clinic. She had been diagnosed with hairy cell leukemia 5 years ago. The patient had received rituximab and cladribine and was in complete remission. At the present time, she was not receiving any treatment for hairy cell leukemia. She had a history of cutting her finger while cleaning and preparing a sheep’s head and one week later, a non-healing lesion developed on her right second finger. Four months after the lesion’s appearance, she visited a surgeon. The lesion was removed with a shave excision, and the pathology reported it as granulation tissue. One month later, a rapidly growing, lobulated mass recurred at the site of the shaved biopsy, which grew to approximately 6x10 cm after several weeks (Figure 1). She visited a family medicine physician and was referred to a surgeon for an incisional biopsy to rule out possible malignancies. However, during the operation, the surgeon decided to amputate the digit due to the broad base of the tumor and tissue fragility and sent it to a pathology laboratory. The histopathologic examination revealed vacuolated epidermal cells with eosinophilic inclusion bodies in some keratinocytes (Figure 4). The pathology result in addition to the patient’s history of the previous contact with sheep was consistent with the diagnosis of orf disease. Two weeks after the surgery, signs of recurrence were noticed, and the patient was referred to a dermatologist (Figure 2). Recurrent lesions were treated with cryotherapy (every two weeks) and topical imiquimod cream (three times a week). Despite treatment with topical imiquimod cream

FIGURE 1 Giant orf lesion on the dorsum of the index finger of the right hand

FIGURE 2 Orf lesion recurred after 2 weeks following the amputation

FIGURE 3 Complete resolution after 10 weeks of treatment with subcutaneous injections of interferon alfa-2a and topical imiquimod cream 5%
and two sessions of cryotherapy, the lesions enlarged after one month, and new lesions began to appear at the site of the amputation. She was prescribed systemic subcutaneous injections of interferon alfa-2a (3 million IU twice weekly) and topical imiquimod cream 5% daily. Treatment was well tolerated by the patient with no complications except for a mild fever the first night after each injection. Four weeks after starting the interferon, remarkable shrinkage of lesions was observed. As a result, the interferon injections were reduced to 3 million IU weekly and continued for 6 more weeks when all lesions were resolved (Figure 3). No new lesions were noted during the six months of follow-up.

3 | DISCUSSION

We reviewed the literature in PubMed/Medline database for articles published from inception up to 2/8/2022 regarding cases of orf in immunocompromised patients by using the following keywords:

Orf, contagious pustular dermatitis, contagious ecthyma, infectious labial dermatitis, ecthyma contagiosum, thistle disease, scabby mouth, immunosuppressed, immunosuppression, immunocompromised, immuno-compromised, immuno-suppressed, immunocompetent.

Out of the retrieved articles, we included 14 studies. Twelve (85.71%) males and two (14.28%) females with a mean age of 52.5 ± 11.31 were enrolled. The majority of patients (n = 8, 57.14%) had a history of organ transplants and most of them had a history of contact with sheep. The characteristics of the included studies are summarized in Table 1.

Human orf is a self-limited skin infection caused by a parapoxvirus and transmitted to humans through contact with infected animals such as sheep and goats or contaminated fomite. The virus from infected animals is proposed to transmit to human skin by cuts and abrasions. Orf lesions are most frequently found on the exposed areas of the human skin that can be in contact with animals. Orf lesions can be painful. Notably, secondary bacterial infections can occur at the site of skin openings. Orf lesions usually regress and heal spontaneously in 3–6 weeks with no scarring. Previous studies indicated that Orf in humans can be misdiagnosed and they are mostly over-treated with undesired high costs. There has not been any report of mortality from Orf in humans.

However, in immunocompromised patients, the lesions may be giant (tumor-like), long-lasting, and resistant to treatment. Amputation should only be considered as the last chance remedy in severe cases with no response to treatment. Histological findings include epithelial hyperplasia, intracellular viral inclusions, and prominent dermal vasculature. It should be noted that these findings are nonspecific, and a definite diagnosis can be made by PCR.

Openet al. proposed the name “orf progressiva” to describe the destructive and progressive nature of this type of giant orf and its resistance to treatment.

Treatment options considered for giant orf in immunocompromised patients often include surgical excision, cryotherapy, topical imiquimod, topical idoxuridine 40% application, topical and intralesional cidofovir, intralesional and systemic interferon injection.
| First author and year of publication | Gender and age (years) | Past medical history | Lesion type | Source | Treatment                                                                 | Results                                                                 |
|--------------------------------------|------------------------|----------------------|-------------|--------|---------------------------------------------------------------------------|-------------------------------------------------------------------------|
| Opene, 2021                          | Male, 43               | Kidney transplant 3 years ago | Friable fungating mass | Lamb    | Topical imiquimod, oral valacyclovir                                      | Complete resolution of lesion                                           |
| Harms, 2019                          | Male, 48               | Liver transplant     | Exophytic, ulcerated tumor with hemorrhagic oozing | Lamb    | Shave removal was performed, and the base was cauterized. Topical imiquimod | Complete resolution of lesion                                           |
| Kostopoulos, 2018                    | Male, 65               | Rheumatoid arthritis (RA) | Erythematous nodules that exhibited spontaneous outflow of serous fluid. | Sheep   | Surgical debridement, immunosuppressive drugs were discontinued except methylprednisolone | Improvement of lesions after 10 days.                                   |
| Polivka, 2017                        | Female, 58             | Cadaveric kidney transplant | Tumor-like lesion | N/A     | Valaciclovir (3 g/day) and imiquimod (once a day for 5 days a week) and a two-fold reduction in the dose of immunosuppressive drugs (tacrolimus 4 mg, day and mycophenolate mofetil 500 mg/day) had no effects. Weekly open-spray cryotherapy (one cycle: 200 s) | Complete regression of lesions                                          |
| Ertekin, 2017                        | Male, 68               | Chronic lymphocytic leukemia (CLL) | Exophytic, pinkish gray, weeping nodule | Sheep   | Surgical removal, oral valacyclovir (1 g 3 times daily) and imiquimod cream 5% (3 times weekly), intralesional interferon alfa-2a injections (3 million IU twice weekly), systemic subcutaneous injections of interferon alfa-2a (3 million IU twice weekly) | Complete resolution                                                   |
| Rørdam, 2013                         | Male, 45               | psoriatic arthritis | tumor | Sheep   | surgical removal, cryotherapy (liquid nitrogen), with a freezing time of 30 s, applied twice. Etanercept was discontinued, imiquimod on a daily basis | Significant improvement                                                  |
| Zaharia, 2010                        | Male, 61               | kidney transplant    | Tumor-like lesion | Sheep   | immunosuppressive treatment was decreased, local treatment of orf with imiquimod 5% cream was started. | Complete healing was obtained 6 weeks later                             |
| Ara, 2008                            | Male, 66               | kidney transplant    | Initially papule that developed into tumoral lesion | Sheep   | topical imiquimod 5% cream 3 times per week.                              | Complete resolution after 16 weeks                                      |
| Geerinck, 2001                       | Female, 39             | renal transplant     | Nodule that then enlarged to a large exophytic lesion | Sheep   | cidofovir cream,                                                          | Significant improvement                                                |
| Degraevea, 1999                      | Male, 48               | renal transplantation | nodule | Mutton | Excision, topical idoxuridine, Cryotherapy was started using the open spray technique (2 cycles of 60 s initially) with an interval of 1 week | complete regression                                                     |
Surgical strategies often cause a delay in the healing process with a high rate of recurrence. In some cases, giant orf lesions are misdiagnosed as skin cancers and lead to amputation. Therefore, physicians must be aware of tumor-like presentations of giant orf in immunocompromised patients to avoid aggressive surgical procedures and potential morbidity. Most progressiva orf patients, subjected to surgical treatment, require serial excisions or combination medical therapy for complete remission of the condition. Hence, surgical procedures are not recommended as the first line of treatment for these patients. Based on the results of our literature review, the majority of cases that showed large-sized tumor-like lesions of orf had a history of organ transplant.

We observed a complete resolution with systemic interferon alfa-2a injections combined with topical imiquimod in ten weeks. In a similar case reported by Ertekin et al., this treatment resulted in complete healing in 9 weeks. The antiviral, antiproliferative, and antiangiogenic properties of systemic interferon alfa-2a result in complete regression of the lesions, making it a suitable option for treatment of recalcitrant giant orf in immunocompromised patients.

In conclusion, immunocompromised patients may experience giant, persistent, and atypical lesions of orf disease. Our case highlights the importance of considering orf as a differential diagnosis, especially in immunocompromised patients complaining of a nodule or tumor-like lesions with a past history of close contact with animals such as sheep and goats or a history of cutting a body part through meat cleaning. When facing such lesions, a thorough history including the patient's occupation, close contact with animals, and history of cutting a body part (commonly extremities) should be taken from the patient. Our case is unique in that it presents a case of recalcitrant orf that persisted even after amputation which was successfully treated with interferon alfa-2a. Before amputation in orf cases, a thorough assessment and consultation with infectious disease specialists, surgeons, and dermatologists should be done. Physicians should be aware of the rare presentation of diseases particularly in immunocompromised patients in order to avoid misdiagnosis.

**TABLE 1 (Continued)**

| First author and year of publication | Gender and age (years) | Past medical history | Lesion type | Treatment | Results |
|--------------------------------------|-----------------------|----------------------|-------------|-----------|---------|
| Peeters, 1998 | Male, 44 | renal transplantation to left eye | Hypertrophic lesion with central necrosis at the right thumb | Topical idoxuridine 40%, cryotherapy | Improvement of the lesion |
| Tan, 1991 | Male, 30 | Nezelof's syndrome | Tumor-like lesion | Shear excision, digital amputation, topical imiquimod cream, and systemic subcutaneous interferon alfa-2a | Successful treatment |
| Savage, 1972 | Male, 65 | Lymphoma | Tumor-like lesion | Shear excision, digital amputation, topical imiquimod cream, and systemic subcutaneous interferon alfa-2a | Improvement of lesions |
| Hunskiar, 1986 | Male, 55 | Chronic lymphocytic leukemia | Initially an ulcer that developed into nodule | Shear excision, digital amputation, topical imiquimod cream, and systemic subcutaneous interferon alfa-2a | Improvement of lesions |
| Saeidi, 2022 (Current case) | Female, 70 | Hairy cell leukemia | Enlarging tumor | Shear excision, digital amputation, topical imiquimod cream, and systemic subcutaneous interferon alfa-2a | Improvement of lesions |

**AUTHOR CONTRIBUTIONS**

All authors contributed to the preparation and finalization of this article. VS, EA, YK, and AG contributed to writing the article and study design. YK and AG contributed to literature review. AG, YK contributed to final editing.

**ACKNOWLEDGMENTS**

The authors would like to express their gratitude to the staff of the Rasool Akram Medical Complex Clinical Research Development Center (RCRDC) for their technical and editorial assistance.
CONFLICT OF INTEREST
None.

DATA AVAILABILITY STATEMENT
Not Applicable.

ETHICAL APPROVAL
This study was approved by the Medical Ethics Committee of our institution.

CONSENT
Written and oral informed consent was obtained from this patient.

ORCID
Vahide Saeidi https://orcid.org/0000-0002-9763-2068
Elahe Aminizade https://orcid.org/0000-0002-2322-9989
Yasamin Kalantari https://orcid.org/0000-0001-8443-4591
Azadeh Goodarzi https://orcid.org/0000-0002-1249-4429

REFERENCES
1. Caravaglio JV, Khachemoune A. Orf review with a focus on advances in diagnosis and treatment. Drugs Dermatol. 2017;16:684-689.
2. Snyder RR, Diven DG. Orf. In: Freedberg IM, Eisen AZ, Wolff K, et al., eds. Fitzpatrick’s Dermatology in Clinical Medicine. 6th ed. McGraw-Hill; 2003:2110-2114.
3. Savage J, Black MN. “Giant” orf of finger in a patient with a lymphoma. Proc R Soc Med. 1972;65:766-768.
4. Johannessen JV, Krogh HK, Solberg I, Dalen A, van Wijngaarden H, Johansen B. Human orf. J Cutan Pathol. 1975;2:265-283.
5. Opene C, Fung MA, Silverstein M. Orf progressive: giant progressive and destructive infections in the immunocompromised. Dermatol Online J. 2021;27(1):1.
6. Ballanger F, Barbarot S, Mollat C, et al. Two giant orf lesions in a heart/lung transplant patient. Eur J Dermatol. 2021;27(12):e515-e516. doi:10.1111/evd.14361
7. Rørdam OM, Grimstad Ø, Spigset O, Ryggen K. Giant orf with prolonged recovery in a patient with psoriatic arthritis treated with etanercept. Acta Derm Venereol. 2013;93(4):487-488. doi:10.2340/00015555-1514
8. Lederman ER, Green GM, DeGroot HE, et al. Progressive ORF virus infection in a renal transplant recipient treated with imiquimod. J Am Acad Dermatol. 2008;58(2 suppl):S39-S40. doi:10.1016/j.jaad.2006.04.027
9. Degraeve C, De Coninck A, Sennesael J, Roseeuw D. Recurrent contagious ecthyma (Orf) in an immunocompromised host successfully treated with cidofovir. J Dermatol. 1999;198(2):162-163. doi:10.1119/00018095
10. Kassa T. A review on human orf: a neglected viral zoonosis. Br J Dermatol. 2017;176:1684-1696.
11. Depaoli MC, Dehner P, Sepehri N, et al. Human orf virus from goats in China, 2012. Vector Borne Zoonotic Dis. 2015;15(3):210-211. doi:10.1089/vbz.2014.1445
12. Rajkomar V, Hannah M, Coulson IH, Owen CM. A case of human to human transmission of orf between mother and child. Clin Exp Dermatol. 2016;41(1):6063. doi:10.1111/ced.12697
13. Harms J, Swick BL, Wanat KA. Pyogenic granuloma-like orf in a transplant patient treated successfully with excision and imiquimod. JAAD Case Rep. 2019;5(6):566-567. doi:10.1016/j.jdercr.2019.02.035
14. Kostopoulos M, Gerodimos C, Batsila E, Kalinou C, Athanassiou P. Orf disease in a patient with rheumatoid arthritis. Mediterr J Rheumatol. 2018;29(2):89-91. doi:10.3113/mjr.29.2.89
15. Polivka L, Moguelet P, Meritet JF, Ouali N, Francis C, Senet P. Giant orf tumour in an immunocompromised patient. J Eur Acad Dermatol Venereol. 2017;31(12):e515-e516. doi:10.1111/jdv.14361
16. P. Orf disease in a patient with rheumatoid arthritis. Rheumatol Int. 1998;18(2):162-163. doi:10.1159/000018095
17. Peeters P, Sennesael J. Parapoxvirus orf in kidney transplantation. Nephrol Dial Transplant. 1998;13(2):531. doi:10.1093/oxfordjournals.ndt.a027869
18. Hunskaar S. Giant orf in a patient with chronic lymphocytic leukaemia. Br J Dermatol. 1986;114(5):631-634. doi:10.1111/j.1365-2133.1986.tb04072.x
19. Ara M, Zaballos P, Sánchez M, et al. Giant and recurrent orf virus infection in a renal transplant patient treated with imiquimod. J Am Acad Dermatol. 2008;58(2 suppl):S39-S40. doi:10.1016/j.jaad.2006.04.027
20. Degraeve C, De Coninck A, Sennesael J, Roseeuw D. Recurrent contagious ecthyma (Orf) in an immunocompromised host successfully treated with cidofovir. J Dermatol. 1999;198(2):162-163. doi:10.1119/00018095
21. Kassa T. A review on human orf: a neglected viral zoonosis. Res Rep Trop Med. 2021;8(12):153-172. doi:10.2147/RRTM.S306446
22. Uzel M, Sasmaz S, Bakaris S, et al. A viral infection of the hand commonly seen after the feast of sacrifice: human orf (orf of the hand). Epidemiol Infect. 2005;133(4):653-657. doi:10.1017/ s0950268805003778
23. Fleming SB, Wise LM, Mercer AA. Molecular genetic analysis of orf virus: a poxvirus that has adapted to skin. Viruses. 2015;7(3):1505-1539. doi:10.3390/v7031505
24. Zhang K, Liu Y, Kong H, Shang Y, Liu X. Human infection with orf virus from goats in China, 2012. Vet Microbiol. 2014;11(1):365-367. doi:10.1089/vbz.2013.1445
25. Rajkomar V, Hannah M, Coulson IH, Owen CM. A case of human to human transmission of orf between mother and child. Clin Exp Dermatol. 2016;41(1):6063. doi:10.1111/ced.12697
26. Yilmaz K, Goletz S, Pas HH, et al. Clinical and serological characterization of orf-induced immunobullous disease. JAMA Dermatol. 2022;158(6):670-674.
27. Chauhan SL, Agnihotri D, Batra K, Sharma M, Kumar T, Sindhu N, Jain VK. Detection and therapeutic management of contagious ecthyma (ORF) in a kid. Clin Case Rep. 2021;9(6):626.
28. Karaali MG, Aksu AE, Polat AK, Gurel MS. Solitary facial lesion of orf in an immunocompromised host successfully treated with etanercept. Acta Derm Venereol. 2013;93(4):487-488. doi:10.2340/00015555-1514
29. Kalantari Y, Goodarzi A. Recalcitrant giant orf recurrence after amputation: A case report and review of the literature. Clin Case Rep. 2022;10:e06209. doi: 10.1002/ccr3.6209